Immunotherapy
Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Published in Drug Week, September 21st, 2007
Planet Technologies, Inc. (NASDAQ:PLNT), a specialty pharmaceutical company whose current operations are focused on the marketing and sale of allergen avoidance products, and Antigen Laboratories, Inc. (Antigen), a privately-held FDA licensed manufacturer of allergenic extracts for immunotherapy, announced that they entered into a definitive agreement under which Planet will acquire Antigen.
Under the agreement, Planet will acquire all of the outstanding equity of Antigen for $10 million, plus the payment of certain liabilities, contingent upon Planet procuring the required financing to complete the transaction.
"The acquisition of Antigen's...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-09-21)
More Articles from Drug Week
- Asthma
Childhood asthma still inappropriately treated in the UK - Breast Cancer
13 Percent of Women Stop Taking Breast Cancer Drug Because of Side Effects - Breast Cancer
Exercise and yoga improves quality of life in women with early-stage breast cancer - Cancer
Fat transforms vitamin C from 'good cop' into 'bad cop' - Cancer
Promising drug combination may help those with ocular melanoma that has spread - Cancer Vaccines
Novel HIV Vaccine Created at The Wistar Institute Funded for Clinical Development - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
